4
8.45
-0.16 (-1.86%)
| Previous Close | 8.61 |
| Open | 8.52 |
| Volume | 153,403 |
| Avg. Volume (3M) | 817,040 |
| Market Cap | 482,791,392 |
| Price / Sales | 3.95 |
| Price / Book | 1.17 |
| 52 Weeks Range | |
| Earnings Date | 20 Mar 2026 |
| Operating Margin (TTM) | -383,007.15% |
| Diluted EPS (TTM) | -3.18 |
| Quarterly Revenue Growth (YOY) | -50.00% |
| Total Debt/Equity (MRQ) | 5.08% |
| Current Ratio (MRQ) | 12.36 |
| Operating Cash Flow (TTM) | -153.26 M |
| Levered Free Cash Flow (TTM) | -90.21 M |
| Return on Assets (TTM) | -22.18% |
| Return on Equity (TTM) | -32.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | 4D Molecular Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
0.9
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.88 |
|
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.88% |
| % Held by Institutions | 95.91% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Novo Holdings A/S | 31 Dec 2025 | 3,650,737 |
| Evergreen Quality Fund Gp, Ltd. | 31 Dec 2025 | 951,474 |
| 52 Weeks Range | ||
| Median | 33.00 (290.53%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 28 Jan 2026 | 33.00 (290.53%) | Buy | 8.60 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 17 Jan 2026 | Announcement | 4DMT Announces New Employment Inducement Grants |
| 07 Jan 2026 | Announcement | 4DMT Provides Company Update and Anticipated Development Milestones for 2026 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |